TWBM Business Summary

TaiHao Medical Inc. (TWBM; 6649.TWO) is a specialized medical technology firm that develops artificial intelligence (AI) solutions for computer-aided detection (CADe) and diagnosis (CADx) in oncology. The company generates revenue primarily through software licensing, system integration fees, and recurring subscription-based SaaS models for its diagnostic platforms. Its business is divided into two primary segments: breast cancer screening, featuring the FDA-cleared "BR-Viewer," "BR-FHUS Smart System," and "BU-CAD" for handheld and automated ultrasound; and lung cancer diagnostics, focused on AI-driven lung nodule detection. TaiHao’s competitive edge lies in its ability to provide real-time navigation and automated BI-RADS categorization, which reduces physician workload by up to 40%. The company competes directly with global players such as Volpara Health, Koios Medical, ScreenPoint Medical, and Qure.ai, positioning itself as a high-accuracy, hardware-agnostic software provider for clinical radiology workflows. Founded in 2013 in Taipei, TaiHao Medical is led by President and CEO Hsin Hung (Simon) Lai, a key figure in the company’s expansion into international markets and its success in securing U.S. FDA 510(k) and Japan’s PMDA clearances. The leadership team comprises a multidisciplinary group of experts in deep learning, biomedical engineering, and clinical medicine, including Marketing Manager Octavia Lin. The company is publicly listed on the Taipei Exchange (TPEx), with a board of directors that prioritizes clinical validation through partnerships with major medical centers and academic research institutions. TaiHao’s ownership structure is characterized by significant insider holdings, reflecting its origins as a founder-led enterprise focused on the digital transformation of precision medicine.